Trial Profile

A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RPESC-RPE-4W (Primary)
Indications Dry age-related macular degeneration
Focus Adverse reactions; First in man
Sponsors Luxa Biotechnology

Most Recent Events

17 Sep 2025 According to Luxa Biotechnology media release, RPESC-RPE-4W recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, for dry AMD.
17 Sep 2025 Results from low-dose cohort 1 presented in the Luxa Biotechnology Media Release.
17 Sep 2025 According to a Luxa Biotechnology media release, results from this study were published in the journal Cell Stem Cell.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com